Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26327611 | 0.86 | PPM1B (0.44) | MAPTALDH1A1KDM4EPOLBPPM1B | |
| SCHEMBL19795515 | 0.85 | RECQL (0.39) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL237380 | 0.84 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL2375356 | 0.84 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL8891623 | 0.84 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL4221 | 0.84 | — | — | |
| SCHEMBL8608076 | 0.83 | ALDH1A1 (0.51) | MAPTALDH1A1POLBMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL30704780 | 0.83 | MAPT (0.49) | MAPTALDH1A1KDM4EPOLBPPM1B | |
| SCHEMBL15443276 | 0.82 | POLB (0.43) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| Hydrochloric Acid SCHEMBL28788727 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030283-B2 | Process for producing 1,1-difluorovinyl cycloaliphatic compounds | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2006-04-18 | — | — | US | claimed |
| US-20050165260-A1 | Process for producing 1,1-difluorovinyl cycloaliphatic compounds | VERSUM MATERIALS US, LLC | 2005-07-28 | — | — | US | claimed |
| EP-1557404-A1 | Process for producing 1,1-Difluorovinyl cycloaliphatic compounds | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2005-07-27 | — | — | EP | claimed |
| EP-3176172-B1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2020-01-29 | — | — | EP | disclosed |
| EP-3176172-B1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2020-01-29 | — | — | EP | disclosed |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2019-03-19 | — | — | US | disclosed |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2019-03-19 | — | — | US | disclosed |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2018-08-09 | — | — | US | disclosed |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2018-08-09 | — | — | US | disclosed |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2018-08-09 | — | — | US | disclosed |
| US-9918985-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-03-20 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-7030283-B2 | Process for producing 1,1-difluorovinyl cycloaliphatic compounds | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20050165260-A1 | Process for producing 1,1-difluorovinyl cycloaliphatic compounds | VERSUM MATERIALS US, LLC | 2005-07-28 | — | — | US | disclosed |
| EP-1557404-A1 | Process for producing 1,1-Difluorovinyl cycloaliphatic compounds | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-5209868-A | Liquid crystal medium | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-05-11 | — | — | US | disclosed |
| US-5175319-A | Antiprotozoa agent, useful for treating malaria, theileriosis, coccidiosis and prophylaxix | BURROUGHS WELLCOME CO. (US) | 1992-12-29 | — | — | US | disclosed |
| US-5053432-A | Antiprotozoa agents; treatment of malaria | BURROUGHS WELLCOME CO. (US) | 1991-10-01 | — | — | US | disclosed |
| EP-0123238-B1 | NAPHTHOQUINONE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-06-10 | — | — | EP | disclosed |
| EP-0123238-A2 | Naphthoquinone derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | MAPT 6/4885ALDH1A1 2834/4885KDM4E 4048/4885 |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | MAPT 6/4885ALDH1A1 2834/4885KDM4E 4048/4885 |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | MAPT 6/4885ALDH1A1 2834/4885KDM4E 4048/4885 |
| US-20050165260-A1 | Process for producing 1,1-difluorovinyl cycloaliphatic compounds | KMO, KCNB1, KCNB2 | MAPT 2170/4885ALDH1A1 3682/4885KDM4E 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.